Can treatment delay end-stage renal disease in children with Alport syndrome? New guidelines have been provided based on our ability to identify individuals at risk of early-onset renal failure and on evidence for blockade of the renin–angiotensin system that has been derived from Alport patient registries, other renal diseases and animal studies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kashtan, C. E. et al. Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatr. Nephrol. http://dx.doi.org/10.1007/s00467-012-2138-4.
Jais, J. P. et al. X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J. Am. Soc. Nephrol. 11, 649–657 (2000).
Gross, O., Netzer, K. O., Lambrecht, R., Seibold, S. & Weber, M. Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling. Nephrol. Dial. Transplant. 17, 1218–1227 (2002).
Jais, J. P. et al. X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a “European Community Alport Syndrome Concerted Action” study. J. Am. Soc. Nephrol. 14, 2603–2610 (2003).
Grodecki, K. M. et al. Treatment of X-linked hereditary nephritis in Samoyed dogs with angiotensin converting enzyme (ACE) inhibitor. J. Comp. Pathol. 117, 209–225 (1997).
Gross, O. et al. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int. 63, 438–446 (2003).
Gross, O. et al. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int. 81, 494–501 (2012).
Ruggenenti, P., Perna, A. & Remuzzi, G. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J. Am. Soc. Nephrol. 12, 2832–2837 (2001).
[No authors listed] Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 349, 1857–1863 (1997).
EU Clinical Trials Register. EARLY PRO-TECT Alport: Early prospective therapy trial to delay renal failure in children with Alport syndrome [online], (2011).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Savige, J. About time—treating children with Alport syndrome. Nat Rev Nephrol 8, 375–376 (2012). https://doi.org/10.1038/nrneph.2012.109
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2012.109
